Prospective long‐term study of hepatitis B virus reactivation in patients with hematologic malignancy

Authors:

Abstract
Background and Aim: To elucidate the clinical characteristics of hepatitis B virus reactivation (HBV‐R), we performed a prospective long‐term study of patients with hematologic malignancy, including both hepatitis B virus (HBV) carriers and those with resolved HBV infection.Methods: Twenty‐one patients with hematopoietic stem‐cell transplants (HSCT) and 36 patients given rituximab‐based chemotherapy were enrolled. Entecavir was administered prophylactically to eight patients with HBV surface antigen (HBsAg). HBV‐DNA was measured every month in 49 patients with resolved HBV infection, and preemptive therapy was given to eight patients with HBV‐R.Results: HBV‐R developed in five (26%) of 19 patients with HSCT and three (10%) of 30 patients given rituximab‐based chemotherapy. HBV‐R occurred a median of 3 months (range: 2–10) after the end of rituximab‐based chemotherapy and 22 months (range: 9–36) after HSCT. HBV‐R did not develop in patients with an antibodies against HBsAg (anti‐HBs) titer exceeding 200 mIU/mL at baseline. Mutations in the “a” determinant region with amino acid replacement were detected in four of the eight patients with HBV‐R. Preemptive therapy prevented severe hepatitis related to HBV‐R. Entecavir treatment was stopped in four patients with HBV‐R. Since the withdrawal of entecavir, HBV‐DNA has not been detected in two patients persistently positive for anti‐HBs. No patient had fatal hepatitis.Conclusions: Proper management of patients with HBsAg or resolved HBV infection prevented fatal hepatitis related to HBV‐R in patients who received immunosuppressive or cytotoxic therapy. Entecavir could be safely discontinued in patients with HBV‐R who had acquired anti‐HBs.
Funding Information
  • KAKENHI (23590985)

This publication has 33 references indexed in Scilit: